Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies

ABSTRACT: This is a phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in combination with full dose erbitux in patients with advanced colorectal cancer who have received no more than 2 prior regimens for metastatic colorectal cancer.

DISEASE(S): Colorectal Cancer,Neoplasms

PROVIDER: 2020028 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

BMS_IM125001_WB_study

Project description:The goal of this study is to define the molecular signatures of prednisolone and BMS-791826 in normal healthy volunteers. IM125001 (NCT03198013) is a phase I, placebo-controlled, double-blind, ascending single and multiple oral dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of bms-791826 and to assess its marker specific pharmacodynamics in relation to prednisolone in healthy males, sponsored by Bristol-Myers Squibb.

2018-02-06 | GSE110161 | GEO

BMS-470539 on human synovial fibroblasts

Project description:Gene expression profile of BMS-470539 on human synovial fibroblasts.

2019-12-16 | GSE98658 | GEO

Methanosphaera sp. BMS

Project description:Methanosphaera sp. BMS Genome sequencing and assembly

| PRJNA310024 | ENA

A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

Project description:This is a phase 1/2, multi-center study with an open-label, dose escalation phase followed by a single-arm expansion phase to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 alone and in combination with ERBITUX (cetuximab) in adults with recurrent and/or metastatic solid tumors.

| 2345844 | ecrin-mdr-crc

Gene expression profiles of ovarian tumor biopsies from Phase I dasatinib trial

Project description:A phase I trial of a SRC kinase Inhibitor, dasatinib, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. Background: We conducted a phase I study of dasatinib, an oral SRC tyrosine kinase inhibitor, in combination with paclitaxel and carboplatin in advanced and recurrent epithelial ovarian cancer (EOC). Methods: The primary objective was to determine the maximum tolerated dose (MTD). Secondary objectives included toxicity, response rate (RR), pharmacokinetics and pharmacodynamics. Based on the 3+3 design, cohorts of 3-6 pts received paclitaxel 175 mg/m2 and carboplatin AUC 6 every three weeks with escalating doses of dasatinib (100, 120, 150 mg daily), followed by an 8 patient expansion cohort. Results: Twenty patients were enrolled between 06/07 and 12/09. The median age was 61 yrs (42-82) with a median of 2 prior regimens (0-6), and 71% had platinum-sensitive disease. There were 3-6 pts in each cohort, and 8 in the expansion cohort. Pharmacokinetics were observed over the first 2 cycles of therapy. One DLT was observed in the 100 mg dasatinib cohort (grade 3 myalgia. Other toxicities in all cycles included neutropenia (95% grade 3-4), thrombocytopenia (35% grade 3-4), and fatigue (10% grade 3). The RR was 45% (complete responses, 3/18(17%); partial responses, 5/18(28%)) and 56% (10/18) had stable disease. The PFS6-month actuarial estimate was 86%. The median PFS and OS were 7.8 and 16.2 months, respectively. Conclusions: Due to the high incidence of myelosuppression with subsequent cycles the recommended phase II dose is 150 mg daily of dasatinib in combination with paclitaxel and carboplatin. The combination was safe with evidence of clinical activity in advanced EOC. Global profiles of expression were characterized using unsupervised clustering methods and gene- and pathway-analyses of differential expression.

2012-04-11 | E-GEOD-37180 | biostudies-arrayexpress

Neoadjuvant BMS-813160, nivolumab, gemcitabine and nab-paclitaxel for pancreatic cancer

Project description:Background: Targeting tumor-associated macrophages through C-C chemokine receptor type 2 (CCRs) in pancreatic ductal adenocarcinoma (PDAC) improves the efficacy of chemotherapy and restores T cell immunity. Methods: We conducted a phase I/II single institution study (NCT03496662) combining chemotherapy gemcitabine and nab-paclitaxel (GnP), an oral CCR2/5 inhibitor BMS-813160 and nivolumab for four 28-day cycles as a neoadjuvant therapy for patients with borderline resectable (BR) or locally advanced (LA) PDAC. The recommended phase 2 dose (RP2D) of BMS-813160 was established in the standard 3+3 design. Primary end points were safety and objective response rate (ORR). Secondary end points included resection rate, progression-free survival (PFS) and overall survival (OS). Results: 8 patients were treated with GnP alone (control arm) and 31 patients (29 response evaluable) were treated at RP2D. No grade 3 or 4 toxicities attributed to nivolumab or BMS-813160 were identified. After all 4 cycles of study treatment (N=26), ORR was 35.7%, 16.7% among BR- and LA-PDAC patients, compared to 0% of control arm patients. 78.6% BR- and 16.7% of LA-PDAC patients who completed study treatment underwent surgical resection. For intent-to-treat analyses, BR-PDAC patients had a mPFS and mOS of 14.6 and 20.4 months respectively; and LA-PDAC patients had a mPFS and mOS of 14.7 and 17 months respectively. Single cell RNAseq analysis showed enhanced proliferating CD4 and CD8 T cells and gene signatures indicative of effector function. Conclusions: Neoadjuvant BMS-813160/nivolumab/GnP was well tolerated and appears to achieve higher ORR and resectability than historical data, warranting a larger randomized phase II study.

2025-03-11 | GSE288533 | GEO

Combination Study of BMS-754807 and Erbitux in Subjects With Advanced or Metastatic Solid Tumors

Project description:The study is expected to identify a safe dose of BMS-754807 to be given in combination with a standard dose of cetuximab and the recommended dose or dose range for Phase II studies. The study is also intended to collect first data on the effects of the combination of BMS-754807 with cetuximab on tumors of patients with colorectal cancer or squamous cell cancer of the head and neck for whom cetuximab-containing therapies have not been effective

| 2072782 | ecrin-mdr-crc

Project description:Isoniazid pharmacokinetics/pharmacodynamics and optimal dose for treatment of Mycobacterium kansasii pulmonary disease

| PRJNA783026 | ENA

Effect of BMS-582949 treatment on gene expression in osteoclasts

Project description:Controlling excessive osteoclastic activity is a promising strategy for many bone disease treatments. Here we report that 10 μM BMS-582949, a clinical p38α inhibitor,dromatically suppresses the osteoclast differentiation in vitro. Our results provide a evidence that BMS-582949 could be a candicdate drug for the therapy of osteolytic diseases.

2024-02-29 | GSE249860 | GEO

Priestia megaterium strain:BMS

Project description:Priestia megaterium strain:BMS Genome sequencing and assembly

| PRJNA243590 | ENA